Hydrea (Hydroxycarbamide)

Hydrea is indicated for several hematologic conditions where abnormal cell growth requires cytoreductive therapy.

• Chronic myeloid leukemia (CML) in patients who are resistant or intolerant to first‑line tyrosine‑kinase inhibitors.
• Sickle cell disease to reduce the frequency of painful vaso‑occlusive crises.
• Polycythemia vera for controlling elevated red blood cell mass and preventing thrombosis.
• Essential thrombocythemia to lower platelet counts and lower thrombotic risk.
• Myelodysplastic syndromes when disease‑modifying therapy is indicated.
• Certain solid‑tumor protocols where hydroxycarbamide is used as a radiosensitizer.

• Hydroxycarbamide acts as a ribonucleotide reductase inhibitor. By binding to the enzyme’s active site, it blocks the conversion of ribonucleotides to deoxyribonucleotides, which are essential building blocks for DNA synthesis. This reduction in deoxyribonucleotide pools limits DNA replication and cell division, preferentially affecting rapidly proliferating hematopoietic cells and malignant clones. The inhibition also leads to accumulation of cells in the S‑phase, enhancing the cytotoxic effect of concurrent radiation or chemotherapy.

Hydroxycarbamide may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common

• Nausea, vomiting or loss of appetite.
• Fatigue and generalized weakness.
• Mild skin discoloration or hyperpigmentation.
• Low white blood cell counts (leukopenia) leading to increased infection risk.
• Elevated liver enzymes indicating mild hepatic irritation.
• Mouth sores or oral mucositis.
• Transient hair thinning or alopecia.

Serious

• Severe bone marrow suppression causing anemia, neutropenia, or thrombocytopenia.
• Acute renal failure or significant rise in serum creatinine.
• Life‑threatening allergic reactions such as anaphylaxis.
• Pulmonary toxicity including interstitial pneumonitis.
• Secondary malignancies, although rare, have been reported.
• Severe gastrointestinal bleeding or ulceration.

Before initiating Hydrea, several precautionary measures should be reviewed to minimize risks and ensure safe use.

• Perform baseline complete blood count and liver function tests, and repeat regularly during therapy.
• Avoid use in pregnant women; the drug is classified as pregnancy category D due to fetal toxicity.
• Use only when the benefits outweigh risks in patients with pre‑existing renal impairment.
• Monitor for signs of infection, as neutropenia can develop rapidly.
• Counsel patients to use effective contraception during treatment and for several weeks after discontinuation.
• Adjust dose or discontinue if severe bone‑marrow suppression occurs.
• Review concomitant medications that may potentiate myelosuppression.

Hydroxycarbamide can interact with other medicines, affecting its efficacy or safety profile.

Avoid

• Concurrent use with other myelosuppressive agents such as azacitidine or chemotherapy drugs, which may exacerbate bone‑marrow toxicity.
• Combining with high‑dose folic‑acid antagonists that could intensify cytopenias.

Use with caution

• NSAIDs or aspirin, which may increase the risk of gastrointestinal bleeding.
• Allopurinol, as it can alter hydroxycarbamide metabolism and raise plasma levels.
• Live vaccines, because immunosuppression may reduce vaccine effectiveness.
• Antacids containing aluminum or magnesium, which might affect oral absorption.